Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback